Maravai LifeSciences is a life sciences tools company that makes and sells reagents, consumables, and services used to develop and manufacture biopharmaceutical drugs, vaccines, and diagnostics. Maravai operates through two segments: TriLink (nucleic acid production, ~64% of revenue) and Cygnus (biologics safety testing, ~36% of revenue). TriLink's flagship product is CleanCap, a patented mRNA capping technology added as a raw material input when drug developers synthesize mRNA for therapeutics, vaccines, or cell and gene therapies. TriLink also sells oligonucleotides, nucleoside triphosphates, specialty enzymes, and contract GMP mRNA manufacturing services. Cygnus sells Host Cell Protein (HCP) ELISA kits — used to detect residual proteins from cell lines used to produce biologics — along with viral clearance kits and custom assay services. HCP testing is a regulatory requirement across every stage of biologics manufacturing, making Cygnus revenues highly recurring. Maravai's business model is built around consumables that customers repurchase repeatedly as they run experiments or manufacture drugs. TriLink GMP revenues are lumpy, tied to clinical program timing, while discovery consumables are more sensitive to biotech funding cycles. Maravai's cost structure is predominantly fixed, making profitability highly sensitive to revenue. The company sells directly to large biopharma customers and through distributors in approximately 60 countries. Maravai's growth strategy focuses on expanding GMP and CDMO revenues with CGT customers, launching new mRNA workflow products, and deepening vertical integration through acquisitions spanning chemistry inputs, enzymes, and AI-driven mRNA design.